VERAXA Biotech

VERAXA Biotech is a clinical-stage biopharmaceutical company based in Switzerland, with research and development operations in Heidelberg, Germany. The company focuses on creating next-generation antibody-based cancer therapies, including antibody-drug conjugates (ADCs) and bispecific T-cell engagers (TCEs). VERAXA utilizes innovative droplet-based microfluidic technology for high-throughput screening of antibodies, enabling rapid testing against complex targets.

Founded in December 2020 through the merger of Velabs Therapeutics GmbH and Araxa Biosciences GmbH, VERAXA leverages advancements from the European Molecular Biology Laboratory (EMBL). The company is committed to developing therapies that offer enhanced safety and efficacy by targeting dual tumor markers. Its pipeline includes several discovery and preclinical programs, with a strong emphasis on ADCs and a lead program in acute myeloid leukemia (AML). VERAXA also provides customized high-throughput antibody screening services and seeks strategic partnerships for biotherapeutics development.